Drug Discovery Services Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Drug Discovery Services Market

Drug Discovery Services Market Size by Process (Target Selection, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small Molecule, Biologics), Therapeutic Area (Oncology, Neurology, Infectious), End User (Pharma, Biotech, Academic) & Region - Global Forecast to 2028

FREE BROCHURE FREE SAMPLE REPORT
Report Code: PH 5682 Mar, 2023, by marketsandmarkets.com

The drug discovery services market is expected to generate a revenue of USD 41.4 billion by 2028, with a revenue of USD 20.7 billion in 2023 to register a CAGR of 14.9%. Opting of services around drug discovery tasks has increased over the years along with the investment in research & development; these are expected to drive market growth. Customers are turning to service providers/contract research organizations due to the costs associated with in-house drug discovery and development. Moreover, advancements in treating diseases are anticipated to boost market expansion. However, a shortage of professionals poses a challenge for outsourcing these activities. Conversely, there is a growing demand, for testing services that could lead to business opportunities.

Attractive Opportunities in the Drug Discovery Services Market

Drug Discovery Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

Drug Discovery Services Market Dynamics

DRIVER: Growing R&D Expenditure in Pharma-Biotech Sector

The upsurge in number of clinical trials registered in the past 10 years has propelled the outsourcing activities around drug discovery. Pharmaceutical companies are investing largely in novel therapeutics development. Biopharmaceutical companies spend resources on research and development to deliver high-quality and innovative products to gain market capital. After studying the recent industry trends, it was observed that the leading pharma companies are increasing their R&D capabilities through significant R&D investments to see capital returns in the long term and through collaborative R&D efforts. In a recent study published by Evaluate Pharma, worldwide pharmaceutical R&D spending was valued at USD 144 billion in 2014, and this figure is estimated to reach USD 285 billion by 2028.

RESTRAINT: Stringent regulations governing drug discovery and animal usage

The major focus of regulatory authorities during drug approval is securing safety and efficacy. Even if these approaches confirm the quality of the products launched in the market, they significantly increase the cost of the drug development process of the final product. For regions with price-sensitive emerging markets, this factor can significantly impact the uptake of a particular drug. Aside from this, multiple legislations that ensure the quality of the product (such as GMP and GLP) usually increase the manufacturing costs. Also, there are strict guidelines govern the usage of animals in drug discovery. Mice, rats, fish, amphibians, and reptiles are the most used animals in any research. Scrutiny regarding the ethical use of animals in research has pushed governments to introduce legislation for animal safety and use, which presents several challenges to the smooth functioning of drug discovery research, and this has reinforced companies to implement other techniques to minimize animal use.

OPPORTUNITY: Technological advancements and new drug discovery techniques

Advent of new technologies is expected to enhance the speed and efficiency of drug- to- market process. Investments in cutting-edge technologies like next-gen proteomics printing of materials, automated lab processes, quantum computing, and DNA technologies for drug development support market expansion. Advanced proteomics tools such as mass spectrometry are recognized for their ability to provide insights, at stages of cancer drug discovery. These tools help in identifying and validating drug targets understanding how drugs work and discovering prognostic biomarkers. 3D-bioprinting technology is considered a powerful tool for building tissue and organ structures for drug discovery. Such advancements in technology will significantly drive the market for drug discovery services.

CHALLENGE: Shortage of Skilled Personnel

The pharmaceutical and biopharmaceutical industry is constantly evolving at a fast pace and professionals need to keep pace with the dynamic changes in the pharmaceutical R&D technologies and methodologies, provide quality services, and comply with good laboratory practices.

Drug discovery service providers encounter challenges, in attracting and retaining trained & skilled professionals due to competition, from pharmaceutical and biotechnology firms well as academic and research institutions for research scientists.

In order to stay competitive businesses must provide salaries and perks which could impact the health and performance of industry players, particularly smaller analytical testing firms. As a result, a shortage of professionals might impede the adoption of technologies and methodologies potentially hindering the growth of the drug discovery services sector, in the future.

Drug Discovery Services: Market Ecosystem

The market ecosystem includes suppliers of materials, drug discovery service providers. End users like pharmaceutical and biotech companies, academic institutions, small CROs (Contract Research Organizations) and clinical laboratories. Raw material suppliers and service providers offer products and services for drug discovery research such as instruments, consumables, assays, kits and accessories for studies like PK/PD (Pharmacokinetics/Pharmacodynamics) ADME (Absorption Distribution Metabolism Excretion) DMPK (Drug Metabolism Pharmacokinetics) among others.

The prominent drug discovery service providers are Laboratory Corporation of America Holdings (US), Eurofins Scientific SE (Germany), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Wuxi AppTec (China), Syngene International Limited (India), Curia Global Inc. (US), Pharmaron Beijing Co., Ltd. (China), Piramal Enterprises Limited (India), Thermo Fisher Scientific Inc. (US), Jubilant Pharmova Limited (India), GenScript Biotech Corporation (US), Shanghai Medicilon Inc. (China), and Frontage Holdings Corporation (US).

Ecosystem Analysis: Drug Discovery Services Market

Drug Discovery Services Market Ecosystem

Source: Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

Based on type, Chemistry Services segment accounted for the largest market share of the drug discovery services market

The drug discovery services market is divided into chemistry services and biology services based on type. In 2022 the chemistry services segment dominated the market. The growth, in this sector can be attributed to the use of chemistry services in stages of early drug development to produce strong drug candidates. The widespread utilization of chemistry, in institutions biotech firms and major pharmaceutical companies further fuels market expansion. On the hand biology services are projected to experience growth.

Based on drug type, small molecule drugs segment accounted for the largest market share of the drug discovery services market

The drug discovery services market is divided into two segments based on the drug type, biologics and small-molecule drugs. In 2022, small-molecule drug type segment generated the largest revenue in the market. Low cost and convenience of working with small molecules, as well as the growing number of start-ups and new entrants concentrating on the development of small-molecule therapies are some of the attributive factors.

Based on therapeutic area, oncology segment accounted for the largest market share of the drug discovery services market

Based on the therapeutic area, the drug discovery services market is broadly segmented into oncology, infectious diseases, neurological diseases, immunological diseases, endocrine and metabolic diseases, respiratory diseases, digestive system diseases, cardiovascular diseases, genitourinary diseases and women’s health, and other therapeutic areas. Oncology is the largest segment in this market owing to the high incidence of cancer, a growing number of research studies on cancer therapeutics, and the focus on bringing innovative cancer drugs into the market.

The North American market is projected to contribute the largest share for the drug discovery services market.

The global drug discovery services market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. With an expected share in 2022, North America is the largest geographic market for drug discovery services, followed by Europe. The market is expanding due to robust pharmaceutical sector, novel R&D projects and high expenditures, growth of biosimilars and generics demand. With numerous international pharmaceutical and biopharmaceutical companies having their headquarters there, North America is the largest pharmaceutical market in the world.

The key players in the region includes Laboratory Corporation of America Holdings (US), Charles River Laboratories International, Inc. (US), Thermo Fisher Scientific (US), Frontage Holdings (US), Pfizer, Inc. (US), AbbVie, Inc. (US), Abbott Laboratories (US), and Johnson & Johnson (US). These companies outsource their drug discovery and drug development services to reduce the cost and time of drug development. This is indicative of the growth opportunities in the North American market.

Drug Discovery Services Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

The drug discovery services market is dominated by a few globally established players such as Laboratory Corporation of America Holdings (US), Charles River Laboratories International Inc. (US), WuXi AppTec (China), and Thermo Fisher Scientific Inc (US), among others, are the key service providers that provided drug discovery services in last few years. The major focus was given to the deals, expansions, and new service launches due to the changing requirements of pharmaceutical and biopharmaceutical companies, academic and research institutes, and other end users across the world.

Scope of the Drug Discovery Services Industry

Report Metric

Details

Market Revenue Size in 2023

$20.6 billion

Projected Revenue Size by 2028

$41.3 billion

Industry Growth Rate

Poised to Grow at a CAGR of 14.9%

Market Driver

Growing R&D Expenditure in Pharma-Biotech Sector

Market Opportunity

Technological advancements and new drug discovery techniques

This report categorizes the drug discovery services market to forecast revenue and analyze trends in each of the following submarkets:

By Process
  • Target Selection
  • Target Validation
  • Hit-to-Lead identification
  • Lead Optimization
  • Candidate Validation
By Type
  • Chemistry Services
  • Biology Services
By Drug Type
  • Small-molecule drugs
  • Biologics
By Therapeutic Area
  • Oncology oncology, infectious diseases, neurological diseases, immunological diseases, endocrine and metabolic diseases, respiratory diseases, digestive system diseases, cardiovascular diseases, genitourinary diseases and women’s health
  • Infectious diseases
  • Neurological diseases
  • Immunological diseases
  • Endocrine and metabolic diseases
  • Respiratory diseases
  • Digestive System diseases
  • Cardiovascular diseases
  • Genitourinary diseases
  • Other Therapeutic Area (psychiatry, dermatology, ophthalmology, and orphan and rare diseases)
By End user
  • Pharmaceutical & Biotechnology companies
  • Academic Institutes
  • Other End Users (small CROs, IVD companies, and clinical laboratories)
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
    • Brazil
    • RoLATAM
  • Middle East and Africa (MEA)

Recent Developments

  • In February 2023, CRL announced an agreement with Flagship Pioneering (US), to accelerate small molecule drug discovery through latter’s Logical AI platform.
  • In January 2023, CRL (US) completed acquisition of SAMDI Tech, Inc. (US), which offered CRL expertise in label-free HTS MS platforms and created a comprehensive library of drug discovery solutions.
  • In April 2022, Charles River Laboratories (US) and Valo Health, a data-driven AI company, launched Logica, an AI-powered drug discovery services

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY 
 
4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 
    4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY (2022) 
    4.3 DRUG DISCOVERY SERVICES MARKET SHARE, BY TYPE (2022) 
    4.4 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
 
5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
           5.2.1 DRIVERS
                    5.2.1.1 Growing R&D expenditure in pharma-biotech sector
                    5.2.1.2 Increasing drug R&D pipeline and rising reliance on outsourcing
                    5.2.1.3 Initiatives for research on rare diseases and orphan drugs
                    5.2.1.4 High cost of in-house drug development
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulations governing drug discovery and animal usage
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Technological advancements and new drug discovery techniques
                    5.2.3.2 Rising demand for specialized testing services among end users
                    5.2.3.3 Patent expiries of key biologics
                    5.2.3.4 High growth prospects in emerging markets
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of skilled personnel
           5.2.5 MARKET TRENDS
                    5.2.5.1 Adoption of AI in drug discovery
                    5.2.5.2 Increased outsourcing to emerging Asian economies
                    5.2.5.3 CRO industry consolidation
                    5.2.5.4 Integrated end-to-end R&D service offerings
    5.3 RANGES/SCENARIOS 
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 
    5.5 VALUE CHAIN ANALYSIS 
    5.6 ECOSYSTEM ANALYSIS 
    5.7 TECHNOLOGY ANALYSIS 
    5.8 PRICING ANALYSIS 
           5.8.1 AVERAGE SELLING PRICE TREND ANALYSIS
    5.9 REGULATORY ANALYSIS 
           5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           5.10.1 THREAT OF NEW ENTRANTS
           5.10.2 THREAT OF SUBSTITUTES
           5.10.3 BARGAINING POWER OF BUYERS
           5.10.4 BARGAINING POWER OF SUPPLIERS
           5.10.5 INTENSITY OF COMPETITIVE RIVALRY
    5.11 KEY CONFERENCES & EVENTS, 2022–2023 
    5.12 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
           5.12.2 BUYING CRITERIA FOR DRUG DISCOVERY SERVICES
 
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS (Page No. - 79)
    6.1 INTRODUCTION 
    6.2 TARGET SELECTION 
           6.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
    6.3 TARGET VALIDATION 
           6.3.1 EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE TO PROMOTE MARKET GROWTH
    6.4 HIT-TO-LEAD IDENTIFICATION 
           6.4.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE
    6.5 LEAD OPTIMIZATION 
           6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION
    6.6 CANDIDATE VALIDATION 
           6.6.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES
 
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE (Page No. - 95)
    7.1 INTRODUCTION 
    7.2 CHEMISTRY SERVICES 
           7.2.1 CHEMISTRY SERVICES TO DOMINATE SERVICE TYPE MARKET
    7.3 BIOLOGY SERVICES 
           7.3.1 RESTRICTIONS ON ANIMAL USAGE TO SLOW MARKET GROWTH
 
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE (Page No. - 102)
    8.1 INTRODUCTION 
    8.2 SMALL-MOLECULE DRUGS 
           8.2.1 SMALL-MOLECULE DRUGS TO HOLD LARGEST MARKET SHARE
    8.3 BIOLOGICS 
           8.3.1 MARKET GROWTH OF BIOLOGICS & CHALLENGES ASSOCIATED WITH DISCOVERY TO DRIVE ADOPTION OF OUTSOURCING SERVICES
 
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 110)
    9.1 INTRODUCTION 
    9.2 ONCOLOGY 
           9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
    9.3 INFECTIOUS DISEASES 
           9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
    9.4 CARDIOVASCULAR DISEASES 
           9.4.1 HIGH MORTALITY RATES PROMPTING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
    9.5 NEUROLOGICAL DISEASES 
           9.5.1 INCREASING INVESTMENTS IN R&D FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET
    9.6 IMMUNOLOGICAL DISORDERS 
           9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
    9.7 ENDOCRINE & METABOLIC DISORDERS 
           9.7.1 INCREASING DIABETIC POPULATION TO BOOST MARKET
    9.8 RESPIRATORY DISORDERS 
           9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
    9.9 DIGESTIVE SYSTEM DISEASES 
           9.9.1 RISING DISEASE INCIDENCE DUE TO LIFESTYLE AND DIETARY CHANGES TO PROPEL MARKET
    9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH 
           9.10.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO BOOST MARKET
    9.11 OTHER THERAPEUTIC AREAS 
 
10 DRUG DISCOVERY SERVICES MARKET, BY END USER (Page No. - 141)
     10.1 INTRODUCTION 
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             10.2.1 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE
             10.2.2 TIER 1 COMPANIES
                        10.2.2.1 High investing capacity to drive growth
             10.2.3 TIER 2 COMPANIES
                        10.2.3.1 Limited investment capacity to slow market growth
             10.2.4 TIER 3 COMPANIES
                        10.2.4.1 Insufficient technical advantages to restrain growth
     10.3 ACADEMIC INSTITUTES 
             10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
     10.4 OTHER END USERS 
 
11 DRUG DISCOVERY SERVICES MARKET, BY REGION (Page No. - 158)
     11.1 INTRODUCTION 
     11.2 NORTH AMERICA 
             11.2.1 US
                        11.2.1.1 US to dominate North American market
             11.2.2 CANADA
                        11.2.2.1 Growing preference to conduct clinical trials in Canada to support market growth
             11.2.3 NORTH AMERICA: RECESSION IMPACT
     11.3 EUROPE 
             11.3.1 GERMANY
                        11.3.1.1 Germany to hold largest share of European market
             11.3.2 UK
                        11.3.2.1 Government-private sector collaborations to boost market
             11.3.3 FRANCE
                        11.3.3.1 Growing number of oncology research projects to propel market
             11.3.4 ITALY
                        11.3.4.1 High number of clinical trials and low drug approval time to augment market
             11.3.5 SPAIN
                        11.3.5.1 Short study start-up times and rising R&D expenditure to augment market
             11.3.6 REST OF EUROPE
             11.3.7 EUROPE: RECESSION IMPACT
     11.4 ASIA PACIFIC 
             11.4.1 CHINA
                        11.4.1.1 Robust pharma industry and presence of key CROs to account for China’s large market share
             11.4.2 JAPAN
                        11.4.2.1 Government initiatives for drug innovation to support market growth
             11.4.3 INDIA
                        11.4.3.1 Low-cost services, availability of skilled workforce, and strong government support to propel market
             11.4.4 AUSTRALIA
                        11.4.4.1 Large number of clinical trials to make Australia a favorable location for drug discovery
             11.4.5 SOUTH KOREA
                        11.4.5.1 Government initiatives and growing R&D activities for drug development to drive growth
             11.4.6 REST OF ASIA PACIFIC
             11.4.7 ASIA PACIFIC: RECESSION IMPACT
     11.5 LATIN AMERICA 
             11.5.1 BRAZIL
                        11.5.1.1 Brazil to dominate Latin American market
             11.5.2 REST OF LATIN AMERICA
             11.5.3 LATIN AMERICA: RECESSION IMPACT
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO BOOST MARKET
             11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 232)
     12.1 OVERVIEW 
     12.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 
     12.3 MARKET SHARE ANALYSIS 
     12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 
     12.5 COMPANY EVALUATION QUADRANT 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
     12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
     12.7 COMPANY FOOTPRINT ANALYSIS 
             12.7.1 COMPANY SERVICE FOOTPRINT
             12.7.2 COMPANY GEOGRAPHIC FOOTPRINT
     12.8 COMPETITIVE SCENARIO 
 
13 COMPANY PROFILES (Page No. - 245)
     13.1 KEY PLAYERS 
             13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        13.1.1.1 Business overview
                        13.1.1.2 Services offered
                        13.1.1.3 Recent developments
                        13.1.1.4 MnM view
                                     13.1.1.4.1 Key strengths
                                     13.1.1.4.2 Strategic choices made
                                     13.1.1.4.3 Weaknesses and competitive threats
             13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                        13.1.2.1 Business overview
                        13.1.2.2 Services offered
                        13.1.2.3 Recent developments
                        13.1.2.4 MnM view
                                     13.1.2.4.1 Key strengths
                                     13.1.2.4.2 Strategic choices made
                                     13.1.2.4.3 Weaknesses and competitive threats
             13.1.3 WUXI APPTEC
                        13.1.3.1 Business overview
                        13.1.3.2 Services offered
                        13.1.3.3 Recent developments
                        13.1.3.4 MnM view
                                     13.1.3.4.1 Key strengths
                                     13.1.3.4.2 Strategic choices made
                                     13.1.3.4.3 Weaknesses and competitive threats
             13.1.4 THERMO FISHER SCIENTIFIC
                        13.1.4.1 Business overview
                        13.1.4.2 Services offered
                        13.1.4.3 Recent developments
             13.1.5 PHARMARON BEIJING CO., LTD.
                        13.1.5.1 Business overview
                        13.1.5.2 Services offered
                        13.1.5.3 Recent developments
             13.1.6 EVOTEC SE
                        13.1.6.1 Business overview
                        13.1.6.2 Services offered
                        13.1.6.3 Recent developments
             13.1.7 EUROFINS SCIENTIFIC SE
                        13.1.7.1 Business overview
                        13.1.7.2 Services offered
                        13.1.7.3 Recent developments
             13.1.8 PIRAMAL ENTERPRISES LIMITED
                        13.1.8.1 Business overview
                        13.1.8.2 Services offered
                        13.1.8.3 Recent developments
             13.1.9 SYNGENE INTERNATIONAL LIMITED
                        13.1.9.1 Business overview
                        13.1.9.2 Services offered
                        13.1.9.3 Recent developments
             13.1.10 CURIA GLOBAL INC.
                        13.1.10.1 Business overview
                        13.1.10.2 Services offered
                        13.1.10.3 Recent developments
             13.1.11 GENSCRIPT BIOTECH CORPORATION
                        13.1.11.1 Business overview
                        13.1.11.2 Services offered
                        13.1.11.3 Recent developments
             13.1.12 JUBILANT PHARMOVA LIMITED
                        13.1.12.1 Business overview
                        13.1.12.2 Services offered
                        13.1.12.3 Recent developments
             13.1.13 FRONTAGE HOLDINGS CORPORATION
                        13.1.13.1 Business overview
                        13.1.13.2 Services offered
                        13.1.13.3 Recent developments
             13.1.14 SHANGHAI MEDICILON INC.
                        13.1.14.1 Business overview
                        13.1.14.2 Services offered
                        13.1.14.3 Recent developments
             13.1.15 AURIGENE DISCOVERY TECHNOLOGIES (DR. REDDY’S LABORATORIES)
                        13.1.15.1 Business overview
                        13.1.15.2 Services offered
                        13.1.15.3 Recent developments
             13.1.16 SYGNATURE DISCOVERY LTD.
                        13.1.16.1 Business overview
                        13.1.16.2 Services offered
                        13.1.16.3 Recent developments
             13.1.17 ONCODESIGN SERVICES
                        13.1.17.1 Business overview
                        13.1.17.2 Services offered
                        13.1.17.3 Recent developments
     13.2 OTHER COMPANIES 
             13.2.1 SELVITA S.A.
             13.2.2 VIVA BIOTECH HOLDINGS
             13.2.3 TCG LIFESCIENCES PVT LTD.
             13.2.4 SHANGHAI CHEMPARTNER CO., LTD.
             13.2.5 DOMAINEX LTD.
             13.2.6 NUVISAN PHARMA HOLDING GMBH
             13.2.7 DALTON PHARMA SERVICES
             13.2.8 ARAGEN LIFE SCIENCES PVT. LTD.
             13.2.9 PROMEGA CORPORATION
 
14 APPENDIX (Page No. - 326)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 
 
 
LIST OF TABLES (307 TABLES)
 
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
TABLE 4 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS
TABLE 5 US: BIOLOGICS GOING OFF-PATENT DURING 2023–2027
TABLE 6 DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2023–2021
TABLE 7 SUPPLY CHAIN ECOSYSTEM
TABLE 8 DRUG DISCOVERY AND DEVELOPMENT PROCESS & COST OVERVIEW (2018 VS 2022)
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 14 DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
TABLE 15 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 16 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2021–2028 (USD MILLION)
TABLE 17 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 22 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 27 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 37 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 42 CHEMISTRY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 BIOLOGY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 ASIA PACIFIC: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 53 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 54 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 64 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2022)
TABLE 65 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 71 NORTH AMERICA DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2022)
TABLE 76 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 77 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2022)
TABLE 82 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 87 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
TABLE 88 DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 89 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 92 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 94 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS (2022)
TABLE 99 DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 100 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2021–2028 (USD MILLION )
TABLE 105 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2021–2028 (USD MILLION)
TABLE 110 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 113 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 115 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 118 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 119 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 120 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 121 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 123 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 124 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 125 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 TOP PHARMA COMPANIES, BY REVENUE (2022)
TABLE 127 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 128 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 129 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 130 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 132 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 133 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 134 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 136 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 137 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 138 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 139 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 141 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 142 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 143 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 144 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 145 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 146 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 147 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 148 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 149 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 150 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 151 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 152 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 153 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 154 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 155 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 157 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 158 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 159 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 161 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 162 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 163 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 164 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 165 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 167 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 168 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 169 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 170 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 171 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 173 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 174 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 175 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 176 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 177 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 178 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 179 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 180 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 181 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 182 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 183 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 184 GERMANY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 185 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 186 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 188 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 189 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 190 UK: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 191 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 192 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 193 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 194 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 195 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 196 FRANCE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022)
TABLE 198 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 199 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 200 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 201 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 202 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 203 ITALY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 204 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 205 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 207 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 208 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 209 SPAIN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 210 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 211 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 212 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 213 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 214 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 215 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 216 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 217 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 218 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 219 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 220 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 221 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 222 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 224 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 225 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 226 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 227 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 228 CHINA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 229 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020 VS. 2022
TABLE 230 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 231 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 232 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 233 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 234 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 235 JAPAN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 236 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 237 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 238 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 239 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 240 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 241 INDIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 242 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 243 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 244 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 245 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 246 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 247 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 248 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 249 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 250 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 251 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 252 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 253 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 254 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 255 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 256 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 257 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 258 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 259 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 260 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 261 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 262 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 263 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 264 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 265 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 266 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 267 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 268 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 269 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 270 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 271 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 272 BRAZIL: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 277 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 278 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 284 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 285 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
TABLE 286 SERVICE PORTFOLIO ANALYSIS: DRUG DISCOVERY SERVICES MARKET (2022)
TABLE 287 GEOGRAPHIC REVENUE MIX: DRUG DISCOVERY SERVICES MARKET (2022)
TABLE 288 DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020–MARCH 2023
TABLE 289 DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2020–MARCH 2023
TABLE 290 DRUG DISCOVERY SERVICES MARKET: EXPANSION: JANUARY 2020–MARCH 2023
TABLE 291 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
TABLE 292 CHARLES RIVER LABORATORIES INTERNATIONAL: BUSINESS OVERVIEW
TABLE 293 WUXI APPTEC: BUSINESS OVERVIEW
TABLE 294 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 295 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW
TABLE 296 EVOTEC SE: BUSINESS OVERVIEW
TABLE 297 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW
TABLE 298 PIRAMAL ENTERPRISES LIMITED: BUSINESS OVERVIEW
TABLE 299 SYNGENE INTERNATIONAL LIMITED: BUSINESS OVERVIEW
TABLE 300 CURIA GLOBAL INC.: BUSINESS OVERVIEW
TABLE 301 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
TABLE 302 JUBILANT PHARMOVA LIMITED: BUSINESS OVERVIEW
TABLE 303 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
TABLE 304 SHANGHAI MEDICILON INC.: BUSINESS OVERVIEW
TABLE 305 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW
TABLE 306 SYGNATURE DISCOVERY LTD: BUSINESS OVERVIEW
TABLE 307 ONCODESIGN SERVICES: BUSINESS OVERVIEW
 
 
LIST OF FIGURES (54 FIGURE)
 
FIGURE 1 RESEARCH DESIGN
FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 3 DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2022
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 7 DRUG DISCOVERY SERVICES MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 8 DRUG DISCOVERY SERVICES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
FIGURE 9 DATA TRIANGULATION METHODOLOGY
FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2022
FIGURE 15 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
FIGURE 16 SMALL-MOLECULE DRUGS HELD LARGEST SHARE OF NORTH AMERICAN DRUG DISCOVERY MARKET IN 2022
FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023–2028
FIGURE 19 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 20 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028
FIGURE 21 ACTIVE PHARMACEUTICAL PIPELINE, 2012–2022
FIGURE 22 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS (2013–2021)
FIGURE 23 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
FIGURE 24 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON DRUG DISCOVERY SERVICES MARKET GROWTH
FIGURE 25 REVENUE SHIFT AND NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS
FIGURE 26 VALUE CHAIN ANALYSIS OF DRUG DISCOVERY SERVICES MARKET: HIT-TO-LEAD IDENTIFICATION AND LEAD OPTIMIZATION PHASES ADD MAXIMUM VALUE
FIGURE 27 ECOSYSTEM ANALYSIS: DRUG DISCOVERY SERVICES MARKET
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DRUG DISCOVERY SERVICES
FIGURE 29 KEY BUYING CRITERIA FOR END USERS
FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS, 2012–2022 (THOUSAND)
FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
FIGURE 32 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011–2021
FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022)
FIGURE 34 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
FIGURE 35 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022)
FIGURE 36 KEY STRATEGIES ADOPTED BY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020–2023
FIGURE 37 DRUG DISCOVERY SERVICES MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS, 2020–2022
FIGURE 39 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2022
FIGURE 40 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
FIGURE 42 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2022)
FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2021)
FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2022)
FIGURE 45 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2021)
FIGURE 46 EVOTEC SE: COMPANY SNAPSHOT (2021)
FIGURE 47 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2022)
FIGURE 48 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2021)
FIGURE 49 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2021)
FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
FIGURE 51 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2021)
FIGURE 52 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
FIGURE 53 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2021)
FIGURE 54 ONCODESIGN SERVICES: COMPANY SNAPSHOT (2021)

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Pharmaceutical Research and Manufacturers of America (PhRMA), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from pharmaceutical and biopharmaceutical industries, CDMOs and CROs, academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions, including North America, Europe, the Asia Pacific, Latin America, and Middle East and Africa. Approximately 70% and 30% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Drug Discovery Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the drug discovery services market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the drug discovery services business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.   

Bottom-up approach: Company Revenue Analysis

Drug Discovery Services Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Approach 2: Secondary Research

  • The size of the drug discovery services market was obtained from secondary sources.
  • The shares of various drug discovery services in the overall market were obtained from secondary data and validated through primary participants to arrive at the total market. 
  • Primary participants validated the numbers.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition:

Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit to lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery services are provided by contract research organizations (CROs) to pharmaceutical companies.

Key Stakeholders

  • Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Drug Discovery Service Providers
  • Venture Capitalists and Investors
  • Contract Research Organizations
  • Government Associations
  • Healthcare Associations/Institutes
  • Business Research & Consulting Service Providers

Report Objectives

  • To define, describe, and forecast the drug discovery services market by type, drug type, process, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to the individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their market shares and core competencies in the global market
  • To track and analyze competitive developments such as product & service launches, partnerships, collaborations, agreements, expansions, and acquisitions in the global market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the RoE market, by country
  • Further breakdown of the RoAPAC market, by country
  • Further breakdown of the RoLA and MEA market, by country

Company Information

  • Detailed analysis and profiling of additional market players (Up to five)

Segment Analysis

  • Further breakdown of the therapeutic area segment as per the service portfolio of prominent players operating in the market.  
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 5682
Published ON
Mar, 2023
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
Latest News
READ MORE
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback